Cross-source evidence timeline
Histrelin research timeline
Follow 10 selected, directly cited source records from December 24, 1991 through January 28, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Histrelin for central precocious puberty-a single surgeon experience.↗
PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 30, 2015 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2021
Literature metadata
Histrelin: in advanced prostate cancer.↗
PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 26, 2010 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00779103↗
PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.↗
Added to PeptideScanner November 16, 2026
Source year
2019
Literature metadata
Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist.↗
PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 1991 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2018
Literature metadata
Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty.↗
PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 1993 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2012
Literature metadata
A review of the use of histrelin acetate in the treatment of prostate cancer.↗
PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 2009 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2007
Regulatory
Drugs@FDA application NDA022058↗
The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026
Source year
2004
Regulatory
Drugs@FDA application NDA021732↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026
Source year
2003
Regulatory
Federal Register notice 03-20949↗
The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin.↗
Added to PeptideScanner November 16, 2026
Source year
1991
Regulatory
Drugs@FDA application NDA019836↗
The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026